Frontline Nilotinib Best Choice for Treatment of Patients With CML-CP

Share this content:
Results from a 5-year follow-up of the phase 3 ENESTnd  study supported the positive benefit-risk profile of nilotinib 300 mg twice daily.
Results from a 5-year follow-up of the phase 3 ENESTnd study supported the positive benefit-risk profile of nilotinib 300 mg twice daily.

Results from a 5-year follow-up of the phase 3 ENESTnd (Evaluating Nilotinib Efficacy and Safety in Clinical Trials-Newly Diagnosed Patients) study supported the positive benefit-risk profile of nilotinib 300 mg twice daily for the treatment of patients with chronic phase chronic myelogenous leukemia (CML-CP).1

In the trial, nilotinib resulted in earlier and higher response rates and a lower risk of progression to accelerated phase/blast crisis than imatinib in patients with newly diagnosed CML-CP.

Investigators sought to determine the long-term outcomes of ENESTnd. Patients were evaluated at a 5-year follow-up.

Results showed that by 5 years, more than half of all patients in each nilotinib arm (300 mg twice daily, 54%; 400 mg twice daily 52%) had achieved a molecular response compared with 31% of patients in the imatinib arm. Nilotinib's benefit was observed across all Sokal risk groups.

RELATED: Once Patent Protection Is Lost, Imatinib as Initial Treatment for CP-CML Will Be Most Cost-effective Strategy

Safety results were consistent with previously reported data. More cardiovascular events occurred in patients who received nilotinib than imatinib. Elevations in blood cholesterol and glucose levels also occurred more frequently in the nilotinib group. Given the high rate of mortality associated with CML progression, few deaths in any arm were associated with cardiovascular events, infections, or pulmonary diseases.

Reference

  1. Hochhaus A, Saglio G, Hughes TP, et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial [published online ahead of print March 4, 2016]. Leukemia. doi: 10.1038/leu.2016.5.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters